EVALUATION OF MELATONIN AND HYALURONIC ACID IN MAXILLARY SINUS AUGMENTATION (A RANDOMIZED CONTROLLED CLINICAL TRIAL)

Maria R. Gendi¹* BDS, Mervat M. Khalil² PhD, Gaafar N. El Halawani³ PhD

ABSTRACT

INTRODUCTION: Rehabilitation of maxillary posterior region with endosseous implants is complicated in the presence of insufficient residual alveolar ridge and maxillary sinus pneumatization. New bone formation without any bone grafting materials has achieved promising results in sinus augmentation. Melatonin and hyaluronic acid suggest satisfying results in enhancing bone defect repair, osseointegration of dental implants.

OBJECTIVES: To evaluate the effectiveness of melatonin and hyaluronic acid combination on bone regeneration in maxillary sinus augmentation.

MATERIALS AND METHODS: 16 patients with missing maxillary posterior teeth indicated for sinus augmentation were divided equally into; group I, received melatonin and hyaluronic acid after sinus membrane elevation with simultaneous implant placement, and group II, did not receive any materials after the procedure. Clinical evaluation were done for pain, swelling, complications, and implant stability and radiographically for vertical bone height gain, bone density, and marginal bone level.

RESULTS: There was a significant increase in bone density on the 1st and 6th months postoperatively in each group and between both groups (p ≤ 0.05). Regarding vertical bone height gain and implant stability, there was significant increase in each group, whereas the increase was insignificant between both groups. Marginal bone level difference between both groups was insignificant. Sinus membrane perforation occurred in one case only which did not affect the procedure completion; and there was no failure or complications along the follow up periods.

CONCLUSION: Melatonin and hyaluronic acid could have a considerable properties regarding bone density in sinus augmentation without complications.

KEYWORDS: Melatonin; Hyaluronic acid; Sinus augmentation.

RUNNING TITLE: Melatonin and hyaluronic acid in maxillary sinus augmentation.

INTRODUCTION

Restoring the posterior maxilla with successful dental implants is complicated in the presence of inadequate residual bone dimensions and maxillary sinus pneumatization (1). Therefore, sinus augmentation is considered an option to overcome such problems (2).

Maxillary sinus augmentation could be done through either lateral window or trans-crestal approaches (3). Superior results were reported for the lateral window approach including a wider range of indications and more advanced biological examination of the variables affecting the newly formed bone which can reach a higher average of bone gain as 6.2 mm (4). Regarding intraoperative complications, the piezoelectric bone-cutting instrument and the lateral trap-door window approach together with a simultaneous implant placement can reduce the possibility of occurrence (5, 6). Maxillary sinus augmentation with simultaneous implant placement could be performed either by grafting or graftless techniques. In the graftless technique, the formation of the new bone depends on two main factors: a stable blood clot of the space left after sinus membrane elevation and the osteogenic potentiality of the sinus membrane. Although the graftless technique suggests reduced cost, less morbidity with minimum infection rates compared with the grafted technique, other studies reported superior results for the grafting technique regarding implant stability, bone height, and bone density (7, 8). So, to improve the quality and the survival rate of the newly formed bone in the graftless-technique, different biomimetic agents were suggested such as enamel matrix derivatives, platelet-rich fibrin (PRF), melatonin, and others (9,10).

Melatonin, or $N$-acetyl 5 methoxytriptamine, is a hormone synthesized and secreted mainly in the pineal gland (11). It is a biomimetic agent that has the ability to promote angiogenesis during bone defects repair (10, 12). Moreover, melatonin has an antioxidant and direct free radical scavenging actions that can inhibit bone resorption by interfering with the osteoclast activity, besides the downregulation of the receptor activator of nuclear factor-B ligand (RANKL)-mediated osteoclast formation and activation. On the other hand, melatonin helps in the bone formation process in several actions like promoting the osteoblast cell differentiation through stimulation of proliferation and synthesis of collagen type I, other bone matrix proteins, and bone markers such as osteocalcin as well as minimizing the period of cells differentiation from 21 to 12 days (13, 14). Also, it can enhance the implant stability in the posterior maxilla with better osseointegration (15).
However, melatonin needs a carrier to increase its half-life in circulation for a longer circulating period in tissues (16). Hyaluronic acid is an ideal carrier material for bone regeneration materials with sinus augmentation procedures. Hyaluronic acid (HA) or Hyaluronan is a naturally occurring high molecular weight linear polysaccharide. It is an unsulfated glycosaminoglycan formed of repeating units of D-glucuronic acid and N-acetyl-d-glucosamine that is synthesized in the extra-cellular matrix of connective tissue, synovial fluid, skin, and other tissues. With cellular and extracellular interactions, interactions with growth factors and osmotic pressure regulation, and tissue lubrication, HA preserves the structural and homeostatic integrity of the tissues. Thus, it is regarded as an ideal biomaterial for different medical applications (17).

Owing to its manipulability, thickness, and biocompatibility, HA can support the regeneration material without displacement, and can increase the new osteoblasts’ count (18). In addition, HA can induce bone formation with osteogenic substances such as bone morphogenetic protein-2 and osteopontin. Thus, bone deposition and remodeling in bone regeneration processes are accelerated in morphogenetic protein-2 and osteopontin. Therefore, in this study, the aim was to evaluate the clinical and radiographic effects of melatonin and hyaluronic acid mixture on bone formation in maxillary sinus augmentation.

MATERIALS AND METHODS
Appropriate Institutional ethical clearance was obtained from the Research Ethical Committee, Faculty of Dentistry, Alexandria University. All participants were asked to sign a written informed consent after explaining the surgical and postoperative study protocol.

Patients’ Selection and Evaluation
Sample Size Calculation
Using PASS program version 20, a minimal hypothesized total sample size of 16 participants admitted to the outpatient clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University. The participants, who were divided into 2 groups, 8 per group, were needed to detect an assumed average proportional difference in the progress in osseointegration using the ISQ scale (Implant Stability Quotient) after using melatonin and hyaluronic acid has been evaluated with favorable results observed related to its components’ characteristics (22).

Methods
Pre-operative Phase
Patients’ history was checked in detail including personal data, medical and dental history. The edentulous area was examined for any horizontal or vertical defects as well as evaluating the overlying soft tissue. Primary alginate impressions were taken to record the jaw relationship and the inter-occlusal space on the study casts. A pre-operative Cone Beam Computed Tomography (CBCT) scan was taken to measure the distance between the alveolar crest and the sinus floor, ridge width, planning of implant size and position as well as detecting any sinus pathology, as shown in (Figure 1). Then scaling and root planning was done.

Figure (1): Preoperative CBCT (coronal cut) showing maxillary posterior alveolar ridge height and width.
**Surgical Phase**

Before surgery, a 30-second rinsing with chlorhexidine gluconate 0.125% mouth wash (Hexitol mouthwash, Arab Drug Company, Cairo, Egypt) was performed. All patients were operated on under local anesthesia using maxillary vestibular and palatal infiltration. Anterior vertical incision of at least 10–15 mm anterior to the wall of the sinus was done with a mid-crestal ridge incision using Bard-Parker blade number 15, and then reflection of a trapezoidal full-thickness mucoperiosteal flap was done. A piezoelectric diamond-coated tip SL1, was attached to an ultrasonic piezoelectric hand-piece of the piezoelectric device to create the lateral trap-door window. The window outlines were determined as follows: the coronal outline depended on the implant length and the position of the posterior superior alveolar artery, the apical outline was about 3 mm above the sinus floor, the mesial outline was 2 mm distal to the anterior wall, and the distal outline followed the future implants number. Sinus membrane elevation was performed using Dentium sinus lift kit manual elevators. The membrane elevation started from the sinus floor, posterior wall, anterior wall, and finally to the superior wall, with a slight elevation that keeps it attached to the underlying Schneiderian membrane to prevent any escape of the trap-door window into the sinus cavity. Also, manual elevators were used to guard and protect the membrane during drilling when implant osteotomies were done following the standard protocol, as shown in (Figure 2). Then the selected implant was carried in place, and a titanium cover screw was inserted after measuring the implant stability with the Osstell ISQ using a smart peg that was matched with each implants size.

![Figure 2](image)

**Figure (2):** Showing DASK manual elevator guard during drilling.

In group I, a 3 mg-melatonin tablets were crushed into powder and a 0.2%-hyaluronic acid gel was added to form a suitable mix. The mix was injected via a plastic syringe to fill the sinus space and around implant apex, whereas in group II the sinus space was left without placing any materials. Moreover for both groups a bioresorbable collagen membrane (collagen membrane adheres directly over the bone without fixation screws) was used to close the window. The flap was sutured at the end of the procedure with interrupted horizontal mattress sutures using 4/0 resorbable vicryl suturing material (ETHICON, Johnsson- Johnsson International, Belgium). (Figures 3, 4).

![Figure 3](image)

**Figure (3):** Showing study group: (A): lateral window outlines, (B): Implant in place with trap-door window, (C): Melatonin and hyaluronic acid mix in place, and (D): A bioresorbable collagen membrane in place with self-adherence with no fixation aids.

![Figure 4](image)

**Figure (4):** Showing control group: (A): lateral window outlines, (B): Implant in place with trap-door window, and (C): A bioresorbable collagen membrane in place with self-adherence with no fixation aids.

**Postsurgical Phase**

All patients were advised to apply ice packs over the face for 10 min on and 10 min off a long the first 24 hours after surgery, elevate their head on 2 or more pillows on the first night of surgery. The diet was liquid only for 2 days then a soft diet for 14 days. Also, they were instructed to avoid chewing on the surgical site, blowing the nose, smoking, balloon blowing, sucking liquid with straw, flying in pressured aircraft or scuba diving, carbonated drinks (3 days), lifting of heavy weights during the first week after surgery, and to open the mouth during sneezing.

Postoperative medications were administrated as following: Amoxicillin 875 mg + Clavulanic acid 125 mg (Augmentin: Amoxicillin 875 mg + Clavulanic acid 125 mg: GlaxoSmithKline, UK) every 12 hours for 7 days, Diclofenac potassium 50 mg ( Cataflam: Diclofenac Potassium 50mg: Novartis-Switzerland) every 8 hours for 5 days, Chlorhexidine antiseptic mouth wash (Hexitol: Chlorhexidine 125mg/100ml, concentration 0.125%: Arabic drug company, ADCO, Cairo, Egypt), started on the second day 2 times daily for 14 days. Xylometazoline HCL 15 ml nasal spray every 8 hours for 7 days, and Otrivin: Xylometazoline HCL spray/nasal Drops 10 ml, Novartis Pharma AG, Basle, Switzerland).
Post-operative Evaluation

1. Pain
Patients were evaluated clinically along the first week after surgery to assess pain using the 4 points of verbal descriptive scale including: no pain, mild, moderate, and severe (23).

2. Swelling
Patients were evaluated clinically along the first week after surgery to assess swelling as following: none (no inflammation), mild (intra-oral swelling confined to the surgical field), moderate (extra-oral swelling in the surgical zone) and severe (extra-oral swelling spreading beyond the surgical zone) (23).

3. Implant stability
Implant stability was recorded immediately and 6 months postoperatively using the Resonance Frequency Analysis via the Osstell ISQ system (Osstell®, integration Diagnostics AB, Goteborg, Sweden).

4. Intra and post-operative complications
Any complications were identified and managed such as bleeding and sinus membrane perforation.

Radiographic evaluation

It was done immediately, 1st, and 6th month postoperatively using Cone-beam computed tomography (On Diamond 3D App-DBM software system (Cybernet, Korea)) to measure:

1. The vertical bone height gain
From the toolbar, the ruler was selected from the measurement section. From the cross-sectional view, the distance from the crestal bone at the implant platform and the bone apical to the implant apex (sinus floor) was calculated. Then, values of the native bone height were subtracted from that taken at the 1st and 6th months to reach the amount of bone height gain for each implant.

2. The bone density in Hounsfield Unit (HU)
Three different cross-sections passing through each implant were taken, density values were measured within a predetermined fixed area within the newly formed bone, then the average density values were taken for each implant with bone density in a known measurement in Hounsfield Unit (HU).

3. The marginal bone level
A standard implant length (10 mm) was used as a reference by adjusting the cross-sectional and panoramic long axis in the center of the implant and bisecting it (showing the buccolingual and mesiodistal dimensions). Mean, standard deviation, minimum and maximum readings were automatically displayed by the system. As shown in (Figure 5, 6).

Prosthetic Phase

After 6 months, the final abutment was placed, then a porcelain fused to metal restorations were cemented.

Statistical analysis of the data (24)

Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp) Qualitative data were described using number and percent. The Kolmogorov-Smirnov test was used to verify the normality of distribution Quantitative data were described using range (minimum and maximum), mean, standard deviation, median and interquartile range (IQR). The Chi-square test was used to compare between two groups with categorical variables, while the Fisher’s Exact was used to correct for chi-square when more than 20% of the cells have expected count less than 5. With normally distributed quantitative variables, the Student t-test was used to compare between two studied groups, the Paired t-test was used to compare between two periods, the ANOVA with repeated measures to compare between more than two periods or stages, and Post Hoc test (Bonferroni adjusted) for pairwise comparisons. The significance of the obtained results was judged at the 5% level.

RESULTS

In this study, 16 sinus augmentation procedures were done for 16 patients and equally divided into 2 groups, study and control groups. All patients were females between 30-50 years. Implants sites were: the first premolar, first molar, and maxillary second molar areas in both groups. in group I, 9 implants were placed in the study and in group II, 8 implants were placed. A standard implant length of 10 mm and a diameter range between 3.5 and 4 mm for both groups. Clinical and radiographic follow up for 6 months were done for all patients.

Only one case in group I had a sinus membrane perforation of < 2 mm which did not affect the procedure completion. The mean height of the alveolar ridge from the marginal crest to the maxillary sinus floor in group I was 5.44 ± 0.47 mm (Range 5.02 – 6.27 mm), while in group II, the mean height of the alveolar ridge from the marginal crest to the maxillary sinus floor was 5.51 ± 0.40 mm (Range 5.07 – 6.24 mm).

1. Clinical Evaluation

1. Pain
For both groups, the pain was evaluated daily for seven days after surgery.

In group I, on the 1st day postoperatively, 7 patients experienced moderate pain, except for one patient who experienced severe pain. On the 2nd, 3rd, and 4th days, the experience of moderate pain decreased by 8, 3, and 0 patients respectively. Mild pain started from the 3rd day and lasted till the 6th day and was experienced by 3 patients on the 3rd day and decreasing from 8, 3, and 1 patient on the 4th, 5th, and 6th days respectively. On the 6th and 7th days, no patients experienced any pain, except for one who still experiencing mild pain till the 6th day.

In group II, on the first two days, all patients experienced moderate pain and only 2 patients continued to have moderate pain till the 3rd day. Mild pain was experienced by 6, 8, and 2 patients on the 3rd, 4th, and 5th respectively. From the 5th day, 6 patients experienced no pain then nobody experienced any pain on the 6th and 7th days respectively.

2. Swelling
For both groups, the swelling was evaluated daily for seven days after surgery.

In group I, on the first two days, all patients experienced moderate swelling and only 3 patients continued to have moderate swelling till the 3rd day. Mild swelling was experienced by 5 patients on the 3rd day, while in the 4th and 5th days it was experienced by all patients. On the 6th and 7th days,
all patients experienced no inflammation except for one patient who continued to have mild swelling till the 6th day.

In group II, on the first two days, all patients experienced moderate swelling and only 2 patients continued to have mild swelling till the 3rd day. Mild swelling was experienced by 6 patients on the 3rd day, while in the 4th and 5th days it was experienced by all patients. On the 6th and 7th days, all patients experienced no inflammation.

For pain and swelling, there was no significant differences between both groups.

3. Intra and Post-operative Complications

No intra-operative complications were recorded regarding bleeding. Sinus membrane perforation occurred only in one case which did not affect the procedure completion. No postoperative complications were observed.

4. Implant Stability

In group I, the mean implant stability quotient (ISQ) was 56.13 ± 5.87 immediately postoperatively and 74.63 ± 9.10 after 6 months.

In group II, the mean ISQ was 57.38 ± 5.24 immediately postoperative and 74.38 ± 7.61 after 6 months.

The increase in ISQ after 6 months in each group was statistically significant in each group, but it was insignificant between both groups, as shown in (Table 1).

Table (1): Comparison between the two studied groups according to ISQ

<table>
<thead>
<tr>
<th>ISQ</th>
<th>Group I (n = 8)</th>
<th>Group II (n = 8)</th>
<th>t</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immediately postop</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min. – Max.</td>
<td>51.0 – 67.0</td>
<td>52.0 – 68.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD.</td>
<td>56.13 ± 5.87</td>
<td>57.38 ± 5.24</td>
<td>0.450</td>
<td>0.660</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>53.50 (51.5 – 60.0)</td>
<td>56.0 (53.50 – 66.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>After 6 months</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min. – Max.</td>
<td>63.0 – 77.0</td>
<td>65.0 – 66.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD.</td>
<td>74.63 ± 3.01</td>
<td>74.38 ± 6.01</td>
<td>0.060</td>
<td>0.953</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>73.0 (67.0 – 81.0)</td>
<td>71.0 (70.0 – 81.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>p0</strong></td>
<td>&lt;0.001*</td>
<td>&lt;0.001*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IQR: Inter quartile range
p: p value for comparing between the studied groups
p0: p value for Paired t-test for comparing between the studied periods
*: Statistically significant at p ≤ 0.05

II. Radiographic Evaluation (Figures 5, 6).

1. Vertical Bone Height Gain (VBHG)

In group I, the mean increase in VBHG was (0.61 ± 0.17 mm) after 1 month and (5.05 ± 0.37 mm) after 6 months.

In group II, the mean increase in VBHG was (0.54 ± 0.10 mm) after 1 month and (5.04 ± 0.47 mm) after 6 months.

The increase in VBHG from the immediate postoperative (baseline), after 1 month and after 6 months was statistically significant in each group, but it was insignificant between both groups, as shown in (Table 2).

Table (2): Comparison between the different studied periods according to bone height gain in each group

<table>
<thead>
<tr>
<th>Bone height gain</th>
<th>Immediate postop. (Baseline)</th>
<th>After 1 month</th>
<th>After 6 months</th>
<th>F</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (n = 8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min. – Max.</td>
<td>5.09 – 8.83</td>
<td>5.65 – 7.58</td>
<td>9.82 – 12.37</td>
<td>1005.38*</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Mean ± SD.</td>
<td>5.86 ± 0.67</td>
<td>6.45 ± 0.76</td>
<td>10.89 ± 0.92</td>
<td>99.04</td>
<td>0.996</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>5.77 (5.23 – 6.39)</td>
<td>6.33 (5.79 – 7.06)</td>
<td>10.94</td>
<td>0.996</td>
<td></td>
</tr>
<tr>
<td><strong>Sig. bet. periods</strong></td>
<td>p1&lt;0.001*</td>
<td>p2&lt;0.001*</td>
<td>p3&lt;0.001*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase from Bas.</td>
<td>6.61 ± 0.17</td>
<td>5.69 ± 0.37</td>
<td>10.94</td>
<td>0.996</td>
<td></td>
</tr>
<tr>
<td>Group II (n = 8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min. – Max.</td>
<td>5.0 – 6.40</td>
<td>5.59 – 6.93</td>
<td>9.94 – 11.50</td>
<td>875.913*</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Mean ± SD.</td>
<td>5.66 ± 0.52</td>
<td>6.20 ± 0.49</td>
<td>10.70 ± 0.57</td>
<td>103.26</td>
<td>0.856</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>5.67 (5.52 – 6.05)</td>
<td>6.12 (5.87 – 6.57)</td>
<td>103.26</td>
<td>0.856</td>
<td></td>
</tr>
<tr>
<td><strong>Sig. bet. periods</strong></td>
<td>p1&lt;0.001*</td>
<td>p2&lt;0.001*</td>
<td>p3&lt;0.001*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase from Bas.</td>
<td>5.54 ± 0.10</td>
<td>5.84 ± 0.47</td>
<td>10.70 ± 0.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>p0</strong></td>
<td>0.339</td>
<td>0.986</td>
<td>10.70 ± 0.57</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

F: F test (ANOVA) with repeated measures, Sig. bet. periods was done using Post Hoc Test (adjusted Bonferroni) IQR: Inter quartile range
p: p value for comparing between the studied periods
p0: p value for Student t-test for comparing between the studied groups
p1: p value for comparing between Baseline and After 1 month
p2: p value for comparing between Baseline and After 6 months
p3: p value for comparing between After 1 month and After 6 months
*: Statistically significant at p ≤ 0.05
2. Bone Density (BD)

In group I, the mean increase in BD was \((187.1 \pm 76.01 \text{ HU})\) after 1 month and \((343.6 \pm 39.40 \text{ HU})\) after 6 months.

In group II, the mean increase in BD was \((99.94 \pm 12.02 \text{ HU})\) after 1 month and \((166.4 \pm 35.64 \text{ HU})\) after 6 months.

The increase in BD from the immediate postoperative (baseline) after 1 month and after 6 months was statistically significant in each group, also the difference in BD increase was statistically significant between both groups (\(p \leq 0.05\)), with superior results regarding group I, as shown in (Table 3).

### Table 3: Comparison between the different studied periods according to bone density in each group

<table>
<thead>
<tr>
<th>Bone density</th>
<th>Immediate postop. (Baseline)</th>
<th>After 1 month</th>
<th>After 6 months</th>
<th>F</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (n = 8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min. – Max.</td>
<td>303.8 – 539.8</td>
<td>394.8 – 810.4</td>
<td>620.0 – 850.1</td>
<td>4.0065*</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Mean ± SD.</td>
<td>420.2 ± 95.4</td>
<td>607.0 ± 154.2</td>
<td>763.9 ± 95.75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>411.4 (333.3 – 514.5)</td>
<td>619.8 (4609.7–7566)</td>
<td>795.3 (6769.8–8411)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sig. bet. periods</td>
<td>(p1&lt;0.001) (p2&lt;0.001) (p3=0.001)</td>
<td>(p1&lt;0.001) (p2&lt;0.001) (p3=0.001)</td>
<td>(p1&lt;0.001) (p2&lt;0.001) (p3=0.001)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Increase from Bas.</th>
<th>187.0 ± 76.0</th>
<th>343.6 ± 39.40</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Group II (n = 8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min. – Max.</td>
<td>307.9 – 749.1</td>
<td>428.5 – 832.8</td>
<td>492.9 – 857.0</td>
<td></td>
</tr>
<tr>
<td>Mean ± SD.</td>
<td>435.1 ± 139.6</td>
<td>535.1 ± 133.6</td>
<td>601.6 ± 122.7</td>
<td>4.52,151*</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>398.7 (3637.4–5496)</td>
<td>483.3 (4638.5–5623)</td>
<td>565.0 (5228.4–6431.3)</td>
<td></td>
</tr>
<tr>
<td>Sig. bet. periods</td>
<td>(p1&lt;0.001) (p2&lt;0.001) (p3=0.001)</td>
<td>(p1&lt;0.001) (p2&lt;0.001) (p3=0.001)</td>
<td>(p1&lt;0.001) (p2&lt;0.001) (p3=0.001)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Increase from Bas.</th>
<th>99.94 ± 12.02</th>
<th>166.4 ± 35.64</th>
<th></th>
<th></th>
</tr>
</thead>
</table>

F: F test (ANOVA) with repeated measures, Sig. bet. periods was done using Post Hoc Test (adjusted Bonferroni).

IQR: Inter quartile range

p: p value for comparing between the studied periods
p0: p value for Student t-test for comparing between the studied groups
p1: p value for comparing between Baseline and After 1 month
p2: p value for comparing between Baseline and After 6 months
p3: p value for comparing between After 1 month and After 6 months

*: Statistically significant at \(p \leq 0.05\)

3. Marginal Bone Level (MBL)

The amount of MBL was evaluated by comparing the 1st month and 6th month postoperative periods after subtracting from the standard used implant length (10 mm).

In group I, the mean difference was \((0.35 \pm 0.15 \text{ mm})\) after 1 month and was \((0.68 \pm 0.21 \text{ mm})\) after 6 months.

In group II, the mean difference was \((0.35 \pm 0.16 \text{ mm})\) after 1 month and was \((0.72 \pm 0.24 \text{ mm})\) after 6 months.

These differences were statistically significant in each group, but were insignificant between both groups.

DISCUSSION

In this study, 16 patients with missed maxillary posterior teeth with insufficient vertical ridge height were selected to perform graftless sinus augmentation procedure using piezo-surgery with immediate implant placement, where melatonin and hyaluronic acid were used as a filling material to evaluate their effects on the bone regeneration procedure.

The minimum residual ridge height in our study was 5 mm which coincides with Mardinger et al study (25) that reported a greater success rates more than 98.7% when the remaining ridge height is > 4 mm compared to lesser success rates as 92% for ridge height < 4 mm.

Along the first week postoperatively, pain and swelling decreased significantly in each group, however there was no significant difference between the study and the control groups. This may be due to the use of piezo-surgery. These results match with Delibasi et al (26) in 2013 who also reported less postoperative pain and swelling when compared between the piezo-surgery and the conventional rotary technique in a direct sinus lifting.

On the other hand, when compared with other studies, it was found to be controversial between studies regarding the hyaluronic acid effect on minimizing pain and swelling. Yilmaz et al (27) evaluated the effectiveness of 0.8% HA (Gengigel®) local application in impacted third molar sockets and measured pain, swelling, and trismus along the first week postoperatively. They found no significant difference between the study and the control groups in facial swelling. However, the amount of pain significantly reduced in HA groups. On contrast, in another study it was reported that 0.8% HA had an anti-inflammatory effect when it was applied immediately after third molar extraction. However, the clinical outcomes regarding pain has no significant differences between the study and control groups after one week (28).

In the present study, only one case exhibited a sinus membrane perforation in group I. It was < 5 mm and represented (6.25%) of all cases. A bio-resorbable collagen membrane was used to repair the perforation with no complications signs along the next 6 months. Moutamed in 2017 (29) reported similar results when compared the sinus membrane perforation in maxillary sinus lifting surgery between the ultrasound and the conventional rotary technique. They reported less membrane perforations rates 9% with piezo-surgery compared to 18% with the conventional rotary DASK technique where a properly integrated implants with no future complications were observed.

In our study, the implant stability was measured using the Resonance Frequency Analysis (RFA) via the Oststell ISQ system, and there was a significant increase ISQ after 6 months for each group. This was explained by new bone apposition at the implant-bone interface (30).

On the contrary, there was no significant difference between both groups regarding implant stability, which means that the implants’ primary stability was not affected by the melatonin and hyaluronic acid. In 2016, El Gamal et al (15) evaluated the local application of 1.2 mg/ mL of melatonin gel in the osteotomy site with immediate-loaded implants. The same results were reported regarding melatonin when compared between the melatonin group and the control group after 3, 6,
and 12 months and no significant difference was observed along these periods between groups. As regarding hyaluronic acid, Taman et al (31) evaluated the effect of hyaluronic acid (Hyadent™) when mixed with autogenous bone graft in alveolar socket preservation, and reported that the ISQ intra-operatively and after 2 months did not affect by hyaluronic acid. Vertical bone height gain increased significantly in each group after 1 and 6 months. However, there was no significant difference between the two groups. Lundgren et al in 2019 (32) explained the same findings when they evaluated the long-term effects of implants placed with graft-less sinus lifting, and concluded that the length of the implant protruding into the sinus cavity is the main factor that determine the amount of bone gain in graft-less technique, recording 10 times stronger than other significant variables. Bone density in this study also showed a significant increase in each group along the follow-up periods, after 1 month and 6 months postoperatively. Different studies discussed the bone density regarding melatonin and HA. Ramírez-Fernández, et al in 2013 (12) studied the radiological and histomorphometric effects of 1.2 mg lyophylized powder of melatonin (Sigui-Aldrich™ – M5250) on angiogenesis during bone defect repair of rabbit tibiae. They found a higher density of the newly formed bone for the melatonin group on the histomorphometric analysis at 4 weeks and a total repair of the bone defects in rabbit tibiae radiographically. Also, in 2018, Alcântara et al (33) evaluated the effects of 1% HA gel on bone repair of human dental sockets and observed a significant difference in bone density between the HA-treated sockets and the control groups after 30 days of extraction. Furthermore, our results were also in agreement with Taman et al (31) who revealed statistically significant radiographic bone density changes between the two studied groups after 2 months and concluded that hyaluronic acid was more efficient in osteoconduction when compared with autogenous bone graft alone in post-extraction socket preservation. On the contrast, Alcântara et al revealed that HA has no significant difference between the studied groups at 90 days effect of HA when compared the bone density of the extraction sockets using HA gel only (33). The conflict in this study is not an actual one because it only used HA without any other material, hence the results are not comparable to our study that supposes an important role of the association between HA and another material to increase the BD more than one month. The significant increase found in group II on the 1st and 6th months were supported by the results of Altimas et al in 2013 (34) who examined the density of the newly formed bone after sinus membrane elevation, with and without bone grafting where the bone density in the non-grafted group showed significant differences starting from 1st week to 6th month postoperatively. Bone density measurements have shown a remarkable scores with a significant difference between both groups at (p ≤ 0.05) along the follow up intervals where the superior results were reported for the study group. The inferior results in group II regarding the increase in BD in our study was in agreement with Fouad et al., (8) who evaluated the difference between the use of xenograft and graftless tenting technique after sinus lift procedure with simultaneous implant placement, and they reported better results in the grafted group when compared with the graftless group; however, the graftless-technique is considered a reliable procedure for sinus lifting with simultaneous implant placement. To the best of our knowledge, melatonin and hyaluronic acid effects on bone density after 6 months were not studied before. So, we suggest more clinical and radiographic studies especially on bone density for a longer follow-up periods. MBL changes in this study after 6 months were (0.68 ± 0.21 mm) in group I and were (0.72 ± 0.24 mm) in group II. These results were supported by Galindo-Moreno et al (35) whose study was to evaluate MBL rates around implants to find the difference between physiological bone loss and peri-implantitis’ bone loss. They found that despite the reported survival rates of dental implants, there is range of a bone loss around implants from 1.5 to 2 mm during the first year of functional loading.

CONCLUSION
Within the limited sample size of this study, melatonin and hyaluronic acid mixture may not share any superior effects as a filling material in maxillary sinus augmentation procedure regarding pain, swelling, implant stability, alveolar bone height gain, and marginal bone level. However, this mixture suggest promising effects that can highly enhance bone density without any complications.

Conflict of interest
The authors declare that they have no conflicts of interest.

Funding
The authors received no specific funding for this work.

REFERENCES


